Exelixis Explains Cabozantinib Thyroid Cancer Delay As Prostate Program Takes Shape
Executive Summary
The results from the event-driven pivotal trial of Exelixis Inc.’s cabozantinib in medullary thyroid cancer will be delayed by three more months, but there is a good chance for a positive outcome.
You may also be interested in...
Exelixis’ Cabozantinib Targets Particularly Sick Thyroid Cancer Patients
Progression-free survival benefit in Phase III trial of rare medullary thyroid cancer was even better than expected, though full safety results are needed to flesh out the drug’s profile.
Exelixis' Cabozantinib Targets Particularly Sick Thyroid Cancer Patients
Progression-free survival benefit in Phase III trial of rare medullary thyroid cancer was even better than expected, though full safety results are needed to flesh out the drug's profile.
Exelixis' Cabozantinib Targets Particularly Sick Thyroid Cancer Patients
Progression-free survival benefit in Phase III trial of rare medullary thyroid cancer was even better than expected, though full safety results are needed to flesh out the drug's profile.